-+ 0.00%
-+ 0.00%
-+ 0.00%

The Zhitong Finance App learned that on September 24, the CDE website showed that Johnson & Johnson (JNJ.US)'s taquitumab (Chinese product name: tolique) will be included in the priority review to treat adult patients with recurrent or refractory multiple myeloma (R/R MM) who have previously received at least first-line treatment (including an anti-CD38 monoclonal antibody and lenalidomide).

Zhitongcaijing·09/24/2026 06:49:05
Listen to the news
The Zhitong Finance App learned that on September 24, the CDE website showed that Johnson & Johnson (JNJ.US)'s taquitumab (Chinese product name: tolique) will be included in the priority review to treat adult patients with recurrent or refractory multiple myeloma (R/R MM) who have previously received at least first-line treatment (including an anti-CD38 monoclonal antibody and lenalidomide).